Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Get Free Report) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 49,126 shares, a drop of 66.5% from the July 15th total of 146,438 shares. Based on an average daily trading volume, of 92,986 shares, the short-interest ratio is currently 0.5 days.
Rocket Pharmaceuticals Trading Down 22.2%
Shares of NASDAQ:RCKTW traded down $0.00 on Friday, hitting $0.00. 10,566 shares of the company were exchanged, compared to its average volume of 39,248. Rocket Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.08.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.
Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.
Featured Articles
- Five stocks we like better than Rocket Pharmaceuticals
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
